

BBSafe[®]

Their health, your tranquility



Non-invasive
prenatal test



cerba
Internacional

What is it?

BBSafe® is the most reliable non-invasive prenatal test on the market that analyzes circulating free fetal DNA.

With a maternal blood sample the test detects the most frequent chromosomal abnormalities in pregnancy: Patau's syndrome (trisomy 13), Edward's syndrome (trisomy 18) and Down's syndrome (trisomy 21) along with microdeletion syndromes.

Accuracy

≥ 99,9 % sensitivity and specificity

	SPECIFICITY	SENSITIVITY
TRISOMY 13 (Patau's syndrome)	99,9 %	99,9 %
TRISOMY 18 (Edward's syndrome)	99,9 %	99,9 %
TRISOMY 21 (Down's syndrome)	99,9 %	99,9 %
SEXUAL CHROMOSOMES	>85 %	99,9 %
*CNVs ≥ 7Mb	99,8 %	74,1 %

* CNVs of a size greater than or equal to 7 Mb are detected.

Process



Maternal blood collection
without risk to the baby

The test can be performed from week 10 (from week 12 for twin pregnancies).



We perform an exhaustive analysis
of this fetal DNA

The fetal DNA is separated from the maternal DNA and sequenced by the latest generation techniques (NGS).



We prepare a personalized report
indicating the risk of suffering
the different anomalies

Results in 4 working days.



3 OPTIONS OF BBSafe®

	STANDARD	PLUS	ADVANCED
Patau's syndrome (trisomy chromosome 13)	○	○	○
Edward's syndrome (trisomy chromosome 18)	○	○	○
Down's syndrome (trisomy chromosome 21)	○	○	○
Turner, Klinefelter, Jakob and triple X syndromes (sex chromosome aneuploidies)	○	○	○
Fetal sex (optional)	○	○	○
Trisomies in chromosomes 9, 15, 16 and 22		○	○
Cri-du-chat syndrome (5p)		○	○
Deletion syndrome 1p36		○	○
Microdeletion syndrome 2q33.1		○	○
Van der Woude syndrome 1q32-q41			○
DiGeorge 2 syndrome 10p14-p13			○
Jacobsen syndrome (delección 11q)			○
Microdeletion syndrome 16p12.2-p11.2			○
Other microdeletion syndromes			○
Autosomal trisomies on all chromosomes			○

MICRODELETION SYNDROMES

Delivery time
(working days)

4 DAYS

4 DAYS

4 DAYS

*In case of twin pregnancies the
information provided may change.



Results

The results are reported as:

Low Risk

or

High Risk

of presenting numerical chromosomal alterations studied.

In case of a High Risk result, Cerba International offers the option of performing an invasive diagnostic test for confirmation at no additional cost.

The identification of fetal sex has a high degree of accuracy.
It is an optional test.

*BBSAFE is a SCREENING technique, not diagnostic, therefore, the results of this test do not provide definitive information on the genetic risks of individuals.





@cerbalaboratorios

@cerbainternacional



Customer Service Contact

atcl@cerba.com

+34 937 272 233

www.cerba.com